Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthofix Medical (OFIX) Research & Development (2016 - 2025)

Orthofix Medical (OFIX) has disclosed Research & Development for 16 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 18.26% year-over-year to $15.4 million, compared with a TTM value of $65.8 million through Dec 2025, down 10.59%, and an annual FY2025 reading of $65.8 million, down 10.59% over the prior year.
  • Research & Development was $15.4 million for Q4 2025 at Orthofix Medical, up from $14.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $23.3 million in Q1 2023 and bottomed at $10.9 million in Q1 2021.
  • Average Research & Development over 5 years is $15.9 million, with a median of $15.7 million recorded in 2025.
  • The sharpest move saw Research & Development soared 107.88% in 2023, then fell 18.26% in 2025.
  • Year by year, Research & Development stood at $13.2 million in 2021, then decreased by 0.69% to $13.2 million in 2022, then soared by 44.02% to $18.9 million in 2023, then decreased by 0.7% to $18.8 million in 2024, then dropped by 18.26% to $15.4 million in 2025.
  • Business Quant data shows Research & Development for OFIX at $15.4 million in Q4 2025, $14.8 million in Q3 2025, and $15.9 million in Q2 2025.